natgillin/translations-raw huggingface dataset:
Thrombocytopenia (G3/4: 1.6%);
Trombocytopeni (G3/4: 1,6%);
Thrombocytopenia (G3/4: 1.6%); Febrile neutropenia (G3/4: NA)
Trombocytopeni (G3/4: 1,6 %); Febril neutropeni (G3/4: NA)
Thrombocytopenia (G3/4: 4.0%);
Trombocytopeni (G3/4: 4,0 %)
Thrombocytopenia (G3/4: 4.0%);
Trombocytopeni (G3/4: 4,0%)
Thrombocytopenia (G3/4: 4.0%); Febrile neutropenia
Trombocytopeni (G3/4: 4,0 %) Febril neutropeni
Thrombocytopenia (G3/4: 5.2%)
Trombocytopeni (G3/4: 5,2 %)
Thrombocytopenia (G3/4: 8.8%); Febrile neutropenia
Trombocytopeni (G3/4: 8,8%); Febril neutropeni
Thrombocytopenia (G3/4: 8.8%); Febrile neutropenia
Trombocytopeni (G3/4: 8,8%); Febril neutropeni.
Thrombocytopenia (G4: 0.2%)
Trombocytopeni (G4: 0,2%)
Thrombocytopenia (G4: 0.5%)
Trombocytopeni (G4: 0,5 %)
Thrombocytopenia (in some cases reversible platelet counts less than 5000 mm3).
Trombocytopeni (vissa fall övergående blodplättsantal understigande 5 000/mm³).
Thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), granulocytopenia (low levels of granulocytes, a type of white blood cell), conjunctivitis (inflammation of the membrane that lines the eyelid), corneal opacity (clouding of the cornea, the transparent layer in front of the pupil), keratitis (inflammation of the cornea), photophobia (increased sensitivity of the eyes to light) and eye pain are also common (seen in between 1 and 10 patients in 100).
Andra vanliga biverkningar är trombocytopeni (lågt antal blodplättar), leukopeni (lågt antal vita blodkroppar), granulocytopeni (lågt antal granulocyter, en typ av vita blodkroppar), konjunktivit (inflammation i slemhinnan som täcker ögonlockens insidor), hornhinneopacitet (grumling av hornhinnan, ögats yttersta genomskinliga hinna), keratit (inflammation i hornhinnan), fotofobi (ökad ljuskänslighet) och ögonsmärta är också vanligt (uppträder hos 1–10 patienter av 100).
thrombocytopenia (low blood platelet counts);
Trombocytopeni (lågt antal blodplättar).
Thrombocytopenia (low number of blood platelets)
Trombocytopeni (brist på blodplättar)
Thrombocytopenia (low number of platelets, which are cells that help blood to clot).
Trombocytopeni (lågt antal blodplättar, vilka är celler som hjälper blodet att levra sig).
Thrombocytopenia (low platelet count)
Trombocytopeni (lågt antal blodplättar)
Thrombocytopenia (platelets < 100,000/mm3)
eller trombocytopeni (trombocyter < 100 000/mm3)
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5,000 per mm3).
Trombocytopeni (några mycket sällsynta fall var svåra med trombocytantal lägre än 5 000 per mm3).
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5.000 per mm3).
Trombocytopeni (några mycket sällsynta fall var svåra med trombocytantal lägre än 5 000 per mm3).
Thrombocytopenia *
Trombocytopeni
Thrombocytopenia a
Trombo- cytopenia
Thrombocytopenia and Immunogencity related to GP IIb/IIIa inhibitors
Trombocytopeni och Immunogenicitet relaterad till GPIIb/IIIa hämmare
Thrombocytopenia and Neutropenia
Trombocytopeni och neutropeni
thrombocytopenia bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
trombocytopeni skelettsjukdom sedan andra orsaker uteslutits såsom brist på vitamin D hepatomegali eller splenomegali
Thrombocytopenia f
Trombocytopenif
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Trombocytopeni har rapporterats som en vanlig biverkning hos patienter som får filgrastim.
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Trombocytopeni har rapporterats som vanligt hos patienter som får filgrastim.
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Vanliga fall av trombocytopeni har rapporterats bland patienter som får behandling med filgrastim.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Mycket vanliga fall av trombocytopeni har rapporterats bland patienter som får behandling med filgrastim.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Trombocytopeni har rapporterats som en mycket vanlig biverkning hos patienter som får filgrastim.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Trombocytopeni har rapporterats som mycket vanligt hos patienter som får filgrastim.
Thrombocytopenia in patients with a positive in-vitro aggregation test in the presence of enoxaparin,
Trombocytopeni hos patienter med ett positivt in vitro-aggregationstest i närvaro av enoxaparin
Thrombocytopenia in patients with a positive in-vitro aggregation test in the presence of enoxaparin,
Trombocytopeni hos patienter med ett positivt in vitro-aggregationstest i närvaro av enoxaparin,
Thrombocytopenia Leukocytosis
Trombocytopen i
Thrombocytopenia Neutropenia Anaemia Lymphopenia
Trombocytopeni Neutropeni Anemi Lymfopeni
Thrombocytopenia occurred in 27.0% of patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombocytopeni uppkom hos 27,0 % av patienterna som fick Pom + LD-Dex och hos 26,8 % av patienterna som fick HD-Dex.
Thrombocytopenia or coagulation defects;
Trombocytopeni eller koagulationsdefekter;
Thrombocytopenia or decreased platelet counts were reported in 24.9% of patients in clinical studies with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (2.6%).
Trombocytopeni, (eller minskat antal blodplättar), rapporterades hos 24,9 % av patienterna i kliniska studier av trastuzumab emtansin och var den vanligaste biverkningen som ledde till avbrytande av behandlingen (2,6 %).
Thrombocytopenia or functional platelet defects
Trombocytopeni eller funktionella trombocytdefekter
Thrombocytopenia Splenic rupture
Trombocytopen i
Thrombocytopenia typically occurs between the 5th and the 21st day following the beginning of treatment with enoxaparin sodium.
Trombocytopeni inträffar vanligtvis mellan det 5:e och 21:a dygnet efter insättandet av behandling med enoxaparinnatrium.
Thrombocytopenia was Grade 3 or 4 in 20.7% of patients who received Pom + LD-Dex and in 24.2% who received HD-Dex.
Trombocytopeni var av grad 3 eller 4 hos 20,7 % av patienterna som fick Pom + LD-Dex och hos 24,2 % som fick HD-Dex.
Thrombocytopenia was reported in approximately 40% of subjects in clinical studies with Kyprolis and approximately 20% of subjects had grade ≥ 3 events.
Trombocytopeni rapporterades hos omkring 40 % av försökspersonerna i kliniska studier med Kyprolis och ca 20 % av försökspersonerna hade biverkningar ≥ grad 3.
Thrombocytopenia#
Trombocytopeni#
Thrombocytopenia*
Trombocytopeni
Thrombocytopenia*, coagulopathy*.
Trombocytopeni*, koagulopati*.
Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*
Trombocytopeni*, Febril neutropeni, Neutropeni*, Leukopeni*, Anaemi*, Lymfopeni
Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*
Trombocytopeni*, Febril neutropeni, Neutropeni*, Leukopeni*, Anemi*, Lymfopeni
Thrombocytopenia*, Neutropenia*, Anaemia*
Trombocytopeni*, Neutropeni*, Anemi
thrombocytopenia,
trombocytopeni,
Thrombocytopenia, anaemia and leukopenia
trombocytopeni, anemi och leukopeni
thrombocytopenia, anaemia, leukopenia
Febril neutropeni, trombocytopeni, anemi, leukopeni
Thrombocytopenia, eosinophilia
Sällsynta: Trombocytopeni, eosinfili
thrombocytopenia, eosinophilia
trombocytopeni, eosinofili
Thrombocytopenia, leucopenia, eosinophilia
peni, leukopeni,
Thrombocytopenia, leucopenia, eosinophilia
Trombocyto- peni, leukopeni, eosinofili
Thrombocytopenia, Leukopenia, Haemolysis*
Trombocytopeni, leukopeni, hemolys
thrombocytopenia, leukopenia, leukocytosis, haemorrhagic diathesis
trombocytopeni, leukopeni, leukocytos, hemorragisk diates
thrombocytopenia, neutropenia (blood disorders)
trombocytopeni, neutropeni (blodrubbningar)
thrombocytopenia, neutropenia, anaemia, leukopenia
trombocytopeni, neutropeni, anemi, leukopeni
thrombocytopenia, neutropenia, leukocytosis, polycythaemia, lymphopenia
trombocytopeni, neutropeni, leukocytos, polycytemi, lymfopeni
Thrombocytopenia, neutropenia, leukopenia, lymphopenia
Trombocytopeni, neutropeni, leukopeni, lymfopeni
Thrombocytopenia, or decreased platelet counts, was commonly reported with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (see section 4.8).
Trombocytopeni, (eller minskat antal blodplättar), rapporterades frekvent i samband med behandling med trastuzumab emtansin och var den vanligaste biverkningen som ledde till avbrytande av behandling (se avsnitt 4.8).
Thrombocytopenia, purpura, leukopenia, anemia, methemoglobinemia, agranulocytosis
Trombocytopeni, purpura, leukopeni, anemi, methemoglobinemi, agranulocytos
Thrombocytopenia1
Trombocyto- peni11
Thrombocytopenia1
Trombocytope ni11
Thrombocytopenia1 Leukocytosis1
Trombocytopeni1 Leukocytos1
Thrombocytopenia11
Trombo- cytopeni11
Thrombocytopenia11
Trombocyto- peni11
Thrombocytopenia11
Trombocytope ni11
Thrombocytopenia11
Trombocytopeni1
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25% of patients (15 % of courses).
Trombocytopeni: Allvarlig (trombocyter mindre än 25 x 109/l) hos 25 % av patienterna (8 % av behandlingarna); måttlig (trombocyter mellan 25,0 och 50,0 x 109/l) hos 25 % av patienterna (15 % av behandlingarna).
Thrombocytopenia: Severe thrombocytopenia (Grade 4 - platelets less than 10 x 109/l) occurred in 6 % of patients in 2 % of courses.
Trombocytopeni: Allvarlig trombocytopeni (grad 4 - trombocyter mindre än 10 x 109/l) förekom hos 6 % av patienterna vid 2 % av behandlingskurerna.
Thrombocytopenia; Leukopenia, Pancytopenia
Trombocytopeni, leukopeni, pancytopeni
Thrombocytopenia^, Anaemia, Leucopenias
Neutropeni^, trombocytopeni^, anemi, leukopeni
Thrombocytopeniaa
Thrombocytopenia
Thrombocytopeniaa
Trombo- cytopenia
Thrombocytopeniaa Leukocytosisa
Trombocytope nia Leukocytosa
Thrombocytopeniaa Leukocytosisa
Trombocytopenia Leukocytosa
Thrombocytopeniab
Trombocytopenib
thrombocytopeniab, lymphopeniab
trombocytopenib, lymfopenib
Thrombocytopeniab,c
Trombocytopenib,c
thrombocytopenic
Trombocytopen
Thrombocytosis
Trombocytos
Thrombocytosis (see section 4.4)
Trombocytos (se avsnitt 4.4)
Thromboembo lism (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Tromboemboli (inklusive lungemboli och djup ventrombos) (se avsnitt 4.4)
Thromboemboli sm (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Tromboemboli (inklusive lungemboli och djup ventrombos) (se avsnitt 4.4)
Thromboemboli sm (including pulmonary embolism and deep vein thrombosis) (see section 4.4.)
Tromboemboli (inklusive lungemboli och djup ventrombos) (se avsnitt 4.4)
thromboembolic
tromboemboliska
thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders
tromboemboliska och ischemiska tillstånd, vaskulär hypotoni, blödning, perifera blodkärlsjukdomar
Thromboembolic event
Tromboemboliska händelser
Thromboembolic events
Tromboemboli
thromboembolic events
tromboemboli- ska händelser
Thromboembolic events - arterial and venous
Tromboemboliska händelser – arteriella och venösa
Thromboembolic events are commonly observed in women with advanced breast cancer and have been observed in clinical trials with Faslodex (see section 4.8).
Tromboemboliska händelser är vanligt förekommande hos kvinnor med avancerad bröstcancer vilket har observerats i kliniska prövningar med Faslodex (se avsnitt 4.8).
Thromboembolic events include deep venous thrombosis, thrombophlebitis and pulmonary embolism (see also section 4.4).
Tromboemboliska händelser inkluderar djup ventrombos, tromboflebit och lungemboli (se även avsnitt 4.4).
Thromboembolic events ITP patients
Tromboemboliska händelser ITP-patienter
Thromboembolic events Tabulated list of adverse reactions
Tromboemboliska händelser Biverkningar i tabellform
Thromboembolic events, including pulmonary embolism
Tromboemboliska händelser, inklusive lungemboli
Thromboembolic events: In patients with VWD, there is a risk of occurrence of thromboembolic events, particularly in patients with known clinical or laboratory risk factors.
Tromboemboliska händelser: Hos patienter med VWD finns en risk för uppkomst av tromboemboliska händelser, särskilt hos patienter med kända kliniska eller laboratoriemässiga riskfaktorer.
Thromboembolic reactions such as myocardial infarction (tight band around the chest with feeling like your heart is beating too fast), stroke (muscle weakness in the face, arm, or leg, trouble speaking or understanding others who are speaking), pulmonary embolism (shortness of breath, chest pain and fatigue), deep vein thromboses (pain and swelling in an extremity).
Blodproppsbildning såsom vid hjärtinfarkt (tryck över bröstet med känsla av att hjärtat slår för fort), slaganfall (muskelsvaghet i ansikte, armar eller ben, svårighet att tala eller förstå andras tal, blodpropp i lungorna (andnöd, bröstsmärta och trötthet), djup ventrombos (smärta och svullnad i en extremitet).
Thromboembolis
Tromboemboli
Thromboembolism
Fotosensitivitetsreakti
Thromboembolism (including pulmonary
Tromboemboli (inklusive
Thromboembolism (including pulmonary
Tromboemboli (inklusive lungemboli
Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section 4.4.)
Tromboemboli (inklusive lungemboli och djup ventrombos) (se avsnitt 4.4)
Thromboembolism (increased risk of blood clots)*
Tromboemboli (ökad risk för blodproppar)
Thromboembolism (increased risk of blood clots)*
Tromboembolism (ökad risk för blodpropp)
Thromboembolism (problems with blood clots in the blood vessels) may occur very rarely, usually associated with severe OHSS.
Tromboembolism (problem med att det bildas blodproppar i blodkärlen) kan inträffa, men är mycket ovanligt och inträffar vanligen i samband med svår OHSS.
Thromboembolism (pulmonary embolism, deep vein thrombosis)*
Tromboemboli (lungemboli, djup ventrombos)
Thromboembolism (pulmonary embolism, deep vein thrombosis)*
Tromboembolism (lungemboli, djup ventrombos)
Thromboembolism, usually associated with severe OHSS (see section 4.4).
Tromboembolism, oftast i samband med uttalat OHSS (se avsnitt 4.4).
Thromboembolism:
Tromboemboli:
ThromboGenics NV Gaston Geenslaan 1 B-3001 Leuven Belgium
ThromboGenics NV Gaston Geenslaan 1 B-3001 Leuven Belgien
Thrombolytics
Trombolytika
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Trombolytika: Säkerheten vid samtidig administrering av klopidogrel, fibrin- eller icke-fibrinspecifika trombolytiska medel och hepariner undersöktes hos patienter med akut hjärtinfarkt.
Thrombophlebitis
Vasospasm
thrombophlebitis, flushing, hot flush, hypertension, hypotension
tromboflebit, blodvallning, värmevallning, hypertoni, hypotoni
thrombophlebitis, lymphangitis
tromboflebit, lymfangit
Thrombophlebitis^
Tromboflebit^
Thromboprophylaxis is recommended in patients being treated with Kyprolis in combination with dexamethasone or with lenalidomide and dexamethasone, and should be based on an assessment of the patient’s underlying risks and clinical status.
Trombosprofylax rekommenderas för patienter som behandlas med Kyprolis i kombination med dexametason eller med lenalidomid och dexametason och ska baseras på en bedömning av patientens underliggande risker och kliniska status.
thrombosis
Blodpropp
thrombosis
Perforation av gallblåsana,b
Thrombosis (blood clot) is an uncommon side effect (may affect up to 1 in 100 people) which may result in serious or fatal complications such as heart attack.
Trombos (blodpropp) är en mindre vanlig biverkning (förekommer hos färre än 1 av 100 användare) som kan leda till allvarliga eller dödliga komplikationer som hjärtattack.
Thrombosis (blood clotting).
Trombos (blodpropp)
Thrombosis includes coronary artery thrombosis (blood clot in the heart arteries or within a stent being felt as a heart attack which can also be fatal) and/or thrombosis in the catheter, both of which are rare (may affect up to 1 in 1,000 people).
Trombos omfattar artärtrombos (blodpropp i hjärtats artärer eller i en stent som känns som en hjärtattack och som även kan vara dödlig) och/eller trombos i katetern, varav båda är sällsynta (förekommer hos färre än 1 av 1 000 användare).
Thrombosis*; Pulmonary embolism*
Trombos*; Lungemboli
Thrombosis*†
Trombos
Thrombosis/embolism*
Trombos/embolism
Thrombotic
Trombotisk
Thrombotic and embolic events Arterial thromboembolic events
Trombotiska och emboliska händelser Arteriella tromboemboliska händelser
Thrombotic events
Blodproppar
Thrombotic events
Tromboshändelser
Thrombotic events (abnormal blood clots)
Trombotiska händelser (onormala blodkoagel)
Thrombotic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be derived from the treatment.
Det finns en risk för trombos i denna patientgrupp och denna risk skall noggrant vägas mot den avsedda fördelen.
Thrombotic Microangiopathy
Trombotisk mikroangiopati
Thrombotic microangiopathy (1)
Trombotisk mikroangiopati (1)
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)
Trombotisk mikroangiopati (inklusive trombotisk trombocytopenisk purpura och hemolytiskt uremiskt syndrom)
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome) †
Trombotisk mikroangiopati (inklusive trombotisk trombocytopen purpura och hemolytiskt uremiskt syndrom)
Thrombotic Microangiopathy (TMA)
Trombotisk mikroangiopati (TMA)
Thrombotic microangiopathy (TMA) has been reported in clinical trials of pazopanib as monotherapy, in combination with bevacizumab, and in combination with topotecan (see section 4.8).
Trombotisk mikroangiopati (TMA) har rapporterats i kliniska studier med pazopanib som monoterapi, i kombination med bevacizumab och i kombination med topotekan (se avsnitt 4,8).
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome3
Trombotis k mikroangi opati inklusive trombotisk trombocyt open purpura/he molytiskt uremiskt syndrom3
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome#
Trombotisk mikroangiopati inklusive trombotisk trombocytopen purpura/hemoly- tiskt uremiskt syndrom#
thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
t rombotisk mikroangiopati inklusive trombotisk trombocytopen purpura/hemolytiskt uremiskt syndrom.
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
Trombotisk mikroangiopati inklusive trombotisk trombocytopen purpura/hemolytiskt uremiskt syndrom
thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
trombotisk mikroangiopati inklusive trombotisk trombocytopen purpura/hemolytiskt uremiskt syndrom.
thrombotic microangiopathya,b
Gastrointestinal sjukdom, Proktalgi
Thrombotic microangiopathyh,*
Trombotisk mikroangiopatih,
thrombotic thrombocyto penic purpura, hypopro- thrombin- aemia
trombotisk trombocyto- pen purpura, hypopro- trombinemi
Thrombotic Thrombocytopaenic Purpura (TTP)
Trombotisk Trombocytopen Purpura (TTP)
Thrombotic thrombocytopaenic purpura (TTP) -see section 4.4
Trombotisk trombocyto- pen purpura (TTP)
thrombotic thrombocytopenic purpura
trombotisk trombocytopenia purpura
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, aquired haemophilia A, granulocytopenia, anaemia
Trombotisk Trombocytopen Purpura (TTP) (se avsnitt 4.4), aplastisk anemi, pancytopeni, agranulocytos, allvarlig trombocytopeni, förvärvad hemofili A, granulocytopeni, anemi
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4)
Trombotisk Trombocytopen Purpura (TTP) (se avsnitt 4.4), benmärgssvikt*, aplastisk anemi, pancytopeni, bicytopeni*, agranulocytos, allvarlig trombocytopeni, förvärvad hemofili A, granulocytopeni, anemi, hemolytisk anemi hos patienter med glukos-6- fosfatdehydrogenasbrist (G6PD)* (se avsnitt 4.4)
thrombotic thrombocytopenic purpura, hypoprothrombinaemia
trombotisk trombocytopen purpura, hypoprotrombinemi
through 10.7 years in girls (n=369) and 10.6 years in boys (n=326), 9-15 years of age at time of vaccination (median follow-up of 10.0 years and 9.9 years, respectively);
under 10,7 år hos flickor (n=369) och 10,6 år hos pojkar (n=326), som var 9-15 år vid tidpunkten för vaccination (median uppföljning på 10,0 respektive 9,9 år);
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance
Efter 360 veckors behandling, genomfördes lyckad genotypanalys på virala isolat från 19 av 28 patienter med bekräftad HIV RNA över 400 kopior/ml, och visade inga primära eller ”active site”- mutationer i proteas (aminosyror i position 8, 30, 32, 46, 47, 48, 50, 82, 84 och 90) eller fenotypisk proteashämmarresistens.
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance.
Efter 360 veckors behandling, genomfördes lyckad genotypanalys på virala isolat från 19 av 28 patienter med bekräftad HIV RNA över 400 kopior/ml, och visade inga primära eller ”active site”- mutationer i proteas (aminosyror i position 8, 30, 32, 46, 47, 48, 50, 82, 84 och 90) eller fenotypisk proteashämmarresistens.
through 9.6 years in men (n=918), 16-26 years of age at time of vaccination (median follow- up of 8.5 years); and through 8.4 years in women (n=684), 24-45 years of age at time of vaccination (median follow-up of 7.2 years).
under 9,6 år hos män (n=918), som var 16-26 år vid tidpunkten för vaccination (median uppföljning på 8,5 år); och under 8,4 år hos kvinnor (n=684), som var 24-45 år vid tidpunkten för vaccination (median uppföljning på 7,2 år).
Through 96 weeks in SPRING-2 and FLAMINGO and 144 weeks in SINGLE, no cases of treatment emergent primary resistance to the integrase- or NRTI-class were seen in the dolutegravir-containing arms.
Till och med vecka 96 i SPRING-2 och FLAMINGO och vecka 144 i SINGLE, sågs inga fall av behandlingsorsakad primär resistens mot integrashämmare eller mot NRTI-preparat i grupperna med dolutegravir.
through a plastic tube placed in your vein (intravenous infusion) usually over 90 minutes
genom en plasttub som sitter i din ven (intravenös infusion) vanligtvis under 90 minuter
Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age.
Behandling av dräktiga och digivande djur en gång i månaden minskar antalet loppor och kan också förebygga loppangrepp hos kullen tills den är sju veckor gammal.